COVID-19 oral antivirals will be evaluated through a new national study called PANORAMIC, run by the University of Oxford. The national study is open to individuals living anywhere in the UK who meet the following criteria:

  • have tested positive for COVID-19 using a PCR test
  • have COVID-19 symptoms that started within the last five days
  • are aged 50 and over, or are aged 18 and over with a health condition that puts them at higher risk of getting seriously ill from Covid 19.

The study will test whether these new oral antiviral treatments can help higher-risk people in the early stages of the coronavirus illness recover faster and therefore reduce the number of people admitted to hospital. 50% of patients will be randomised to receive an antiviral and 50% will receive the current standard of care so the study team can see any difference in the health of those who received the antiviral treatment compared to those who did not. All participants take part from their own homes, without needing to visit a clinic or hospital. The oral treatment will be delivered directly to their home by the trial team. All participants will still be able to access any health care that they would normally expect to receive.

Those eligible can sign up for the trial at the study website.


High Risk Individuals

The NHS is offering new antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill.

Sotrovimab is an antibody treatment.

Molnupiravir is an antiviral medicine.

Immunodeficiency UK Update RE Treatments 10th Feb 2022

NHS Treatments for coronavirus (COVID-19) 

England Treatments for coronavirus (COVID-19)

Wales (COVID-19)

Scotland Coronavirus Treatments (COVID-19)

Northern Ireland Treatments for coronavirus (COVID-19) 

Covid-19 Guidance